Your donation will make a difference:
Cystic Fibrosis Trust

Please Log in

Log in

Not a registered user? Register with us

This trial will be added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Gut - CF


Therapeutic category
The type of treatment or therapy being studied. A therapy could range from a medication addressing a particular characteristic of CF to a device or activity e.g. exercise


Trial status

Project in Setup

Full title

Validation of a bowel symptom severity score for cystic fibrosis bowel disease

Cystic fibrosis affects the digestive system and leads to a number of unpleasant symptoms. Those relating to the bowels are often overlooked and can be hard to treat. We are hoping to evaluate a new questionnaire –the CF bowel score (CF-BS)–specifically designed to look at CF bowel disease. We hope it will improve identification and allow us to measure response to treatment. The patient will complete the CF-BS at their routine clinic appointment along with providing relevant clinical information. One group of patients will be sent home with the CF-BS to complete at home and return to us within a week. A final group of patients will be asked to complete the form before and after certain treatments so we can assess how bowel symptoms change over a course of treatment. Once we are happy that the CF-BS questionnaire captures symptoms that affect CF patients it will be distributed to the rest of the patients at the Manchester Adult CF Centre. This will allow us to identify the number of patients with bowel symptoms and allow us to better treat them

Trial type


Length of participation
The length of time a participant will take part in a trial, from the first to the last appointment

1 week

Last edited date

24 January 2018


Manchester NHS Foundation Trust – Wythenshawe Hospital

Sponsor type


Who can take part?



Top inclusion criteria
  • Patients with a proven diagnosis of cystic fibrosis
  • Provision of signed, written and dated informed consent, prior to any study specific procedures.
Top exclusion criteria
  • Pregnant

CF centres running this trial